Please ensure Javascript is enabled for purposes of website accessibility

2 Things That May Boost This Beaten-Down Vaccine Stock

By Adria Cimino - May 20, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This company could benefit from a near-term need -- and a long-term one, as well.

Inovio Pharmaceuticals (INO 6.30%) doesn't look like a potential coronavirus-vaccine leader at the moment. The company initially lost momentum when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on one of its trials last fall.

More recently, the government dropped a plan to fund its phase 3 trial. The U.S. cited the number of vaccines already on the market.

Looks like a dark picture, right? But the story may not be over for Inovio. In fact, there are two things that may offer the company opportunity in the vaccine market. And as a result, they may boost the stock price. Let's take a look at each.

An investor sits at her laptop at home and takes notes on a piece of paper.

Image source: Getty Images.

1. Vaccine demand outside of the U.S.

Inovio clearly won't play a role in U.S. vaccination this year. The Biden administration already bought enough doses of commercialized vaccines from the company's rivals to cover the whole population. And as mentioned above, the government decided not to fund the final stage of Inovio's program due to "rapid deployment of vaccines" in the U.S.

Carving out share in the U.S. market may be a challenge in the future, too. If the U.S. is pleased with market leaders Moderna and Pfizer, the country may continue to order most doses from those players. But there's another big market out there waiting for latecomers such as Inovio. And that's the international market.

So far, only 9.2% of the world's population has received one dose of a coronavirus vaccine, according to Our World in Data. And here, it's impossible for only two players to fulfill demand.

Inovio is planning a global phase 3 trial for its vaccine candidate. It aims to launch the vaccine this summer. Importantly, Inovio said in its recent earnings call that it's in discussions for advance purchase agreements in countries involved in the trial.

Beyond just the fact that many countries need vaccine doses, another factor may work to Inovio's advantage. The vaccine candidate can be kept at room temperature for more than a year -- and it can withstand a temperature of more than 98 degrees Fahrenheit for at least a month.

This makes Inovio's investigational vaccine easier to distribute everywhere -- including countries that don't have infrastructure to maintain cooling through transport and storage. The Moderna and Pfizer vaccines both require cold temperatures.

2. The game-changing potential of its earlier-stage vaccine candidate

International vaccine demand may be a catalyst for Inovio in the coming year if its phase 3 trial is successful. Now let's look at an element that may help the company further down the road. Inovio is conducting preclinical studies on a completely new candidate: a "pan-COVID" vaccine, one that could address today's variants and those of the future.

This could be a game changer because the world wouldn't have to fear the next potential coronavirus strain. The pan-COVID vaccine would be able to handle it. The candidate isn't designed to address a specific variant, like the booster candidate of rival Moderna, for example.

Here's how Inovio created this potential vaccine. Researchers looked at variant sequences over a four-month period across several geographic areas. Then they gathered together the spike protein mutations. From here, Inovio identified a common set of mutations to generate the investigational vaccine.

Preclinical studies showed the candidate produced strong neutralizing antibody and T cell responses against the original coronavirus and three current variants of concern -- the U.K., South African, and Brazilian strains.

The company plans to launch a phase 1/2 trial this year. If trials are successful, Inovio could become a key player in a post-pandemic world, internationally and in the U.S.

Does this make Inovio a buy?

These two elements are definite positives for Inovio and could send the shares soaring -- if they bear fruit. For instance, catalysts could be the signing of advance purchase agreements, positive trial data, and market authorization.

Shares right now are at a low point and have lost 19% year to date. And they're down 58% from a peak back in February. There's potential for gains on any good news.

I still wouldn't advise buying this biotech stock now unless you're a very aggressive investor. Inovio's coronavirus vaccine path has been rocky so far. And Inovio hasn't yet brought a product to market.

I don't think the risk will decline until the company gets a lot closer to that point with one of its vaccine candidates. In the meantime, I'll happily keep it on my watch list.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.62 (6.30%) $0.15
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.53 (2.58%) $1.25
Moderna, Inc. Stock Quote
Moderna, Inc.
$170.22 (-0.93%) $-1.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.